Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #healthcarefinance #infectiousdisease
Saturday, March 7, 2026, 12:22 am / permalink 20307 / 3 stories in 4 days
Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)
White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.